POS0146 PERIPHERAL NEUROPATHY IN PSORIASIS AND PSORIATIC ARTHRITIS: A SINGLE BLIND, CONTROLLED, ELECTROPHYSIOLOGICAL STUDY

Abstract

Background:It is well known that both psoriasis (PsO) and psoriatic arthritis (PsA) causes morbidity and disability in patients’ lives. Additional pathologies such as peripheral neuropathy (PN) may interfere with disease specific symptoms and may increase the burden of disease. Neuropathic complaints of patients with PsO and PsA are observed during patients’ follow-up (1,2). However, the presence of PN in PsO and PsA is not well defined in clinical studies and clinicians might be neglecting this issue.Objectives:Our aim was to investigate the presence of PN by electrophysiological methods and to examine its relationship with neuropathic pain and with treatments in patients with PsO and PsA.Methods:38 patients with PsA, 36 patients with PsO and 37 age&sex-matched healthy volunteers were enrolled into this prospective, single-blind study. Disease activity was assessed with Psoriasis Area Severity Index (PASI) for patients with PsO and with Disease Activity in Psoriatic Arthritis (DAPSA) score for patients with PsA. Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) score was used to evaluate neuropathic pain. All participants were electrophysiologically examined in Electromyography (EMG) Laboratory by an experienced neurologist blinded for study groups.Results:There were no significant differences on patients age, sex and body mass index among 3 study groups (p>0.05). However, disease duration was significantly longer in PsO group compared to PsA group (median 19.1[1-43] years in PsO vs median 7.5[2-29] years in PsA; p<0.01). PN was detected in 7 patients (19.44%) in the PsO group, 14 patients (34.21%) in the PsA group, and in 1 volunteer (2.7%) in the control group (PsO vs control: p<0.05; PsA vs control: p<0.001, PsO vs PsA: p>0.05) (Table 1). Among patients with PsA, 1 patient had ulnar neuropathy and 1 patient had both carpal tunnel syndrome (CTS) and sensory polyneuropathy. All other PNs detected electrophysiologically were CTS. Neuropathic pain was present in 11 patients (30.56%), 20 patients (52.63%) and in 2 volunteers (5.41%) in PsO, PsA and control groups consecutively (PsO vs control: p<0.05; PsA vs control: p<0.001, PsO vs PsA: p>0.05). PN did not show any significant correlation with disease activity or treatments including biological agents.Table 1.Results of peripheral neuropathy and neuropathic pain in control group and patients with PsO and PsAControl Group (n=37)PsO Group (n=36)PsA Group (n=38)p^p+p&CTS1 (%2.70)7 (%19.44)13* (%34.21)0.028a<0.001a0.153aUlnar Neuropathy001 (%2.63)Polyneuropathy001* (%2.63)Total PN1 (%2.70)7 (%19.44)14 (%36.64)0.028a<0.001a0.097aLANSS Score5 (0:13)6.50 (0:16)13 (3:19)0.170b<0.001b0.004bAccording to LANSSlikely neuropathic pain2 (%5.41)11 (%30.56)20 (%52.63)0.005 a<0.001a0.054a*: Both polyneuropathy and CTS were detected in one patient in the PsA group; Data are given as n (%) and median (minimum: maximum); a: Chi-Square Test, b: Kruskal Wallis Test; p^ value: control vs PsO, p+ value: control vs PsA, p& value: PsO vs PsAConclusion:To our knowledge, this is the first study to investigate simultaneously the presence of neuropathic pain and PN by electrophysiological methods in patients with PsO and PsA. We observed PN and neuropathic pain high in patients with PsO&PsA and among them CTS appears as the most prominent neuropathy. Clinicians should keep this in mind during routine care of patients with PsO and PsA, which may improve patient-centred care. Large, prospective studies are needed to understand the characteristics of these neuropathies and its prognosis.